MJNA News 01/09/2017 - 0.1815

Medical Marijuana, Inc. $MJNA News
Last updated 01/09/2017 - 0.1815

Medical Marijuna, Inc. Investment AXIM(R) Biotech Receives Positive PK Data Results for CanChew Plus(R) CBD Gum

Jan 09, 2017
OTC Disclosure & News Service

-

Medical Marijuna, Inc. Investment AXIM(R) Biotech Receives Positive PK Data Results for CanChew Plus(R) CBD Gum

AXIM Biotechnologies Announces Positive Pharmacokinetic (PK) Data Results on Proprietary Delivery Method for Cannabinoids in Chewing Gum

SAN DIEGO, CA --(Marketwired - January 09, 2017) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) has received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, which will be used in upcoming clinical trials with patients suffering from irritable bowel syndrome (IBS).

The single dose study on 10 mg of cannabidiol (CBD) and 30 mg of CBD determined the concentration of CBD in the blood after chewing one CanChew Plus® Gum for thirty minutes in healthy volunteers. The 30 mg dosage showed excellent results and this data will be used to determine the optimal concentration in the IBS patient trial.

"Yet again, AXIM continues to impress the industry with this study on its proprietary delivery method for cannabinoids and ground-breaking research in the field," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "With this data, AXIM will be able to formulate the optimal dosage for its clinical trial products to render the most positive results for their patients."

"AXIM is among just a few companies conducting clinical research on the benefits of cannabinoids. Their research will be the catalyst for change in many sectors of the pharmaceutical industry as we believe that cannabinoid therapeutics has the potential to restructure certain aspects of how medicine will be practiced. We applaud the AXIM team and support continued efforts on this front," added Dr. Titus.

There are very few effective treatments for IBS, which effects between 25 and 45 million people in the United States and around 10-15% of the world population. AXIM intends to bring a pharmaceutical solution to the IBS market, which is estimated to be worth $1.5 billion by 2023.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About AXIM®

AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.

About CanChew® and CanChew Plus®

CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:

Non-habit forming
No prescription needed
Available in all 50 states
Great-tasting mint gum has no artificial sweeteners or preservatives
Non-GMO, gluten free, vegan and kosher
CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.

Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact information

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC-MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Article Names Medical Marijuana, Inc. and AXIM(R) Biotech as Two of "10 Largest Marijuana Companies Raking in Huge Profits"

Jan 06, 2017
OTC Disclosure & News Service

-

Article Names Medical Marijuana, Inc. and AXIM(R) Biotech as Two of "10 Largest Marijuana Companies Raking in Huge Profits"

SAN DIEGO, CA--(Marketwired - January 06, 2017) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company in the United States, today announced that the Company was featured in a recent High Times article, "10 Largest Marijuana Companies Raking in Huge Profits."

Using data from well-respected firm Viridian Capital Advisors, a group of Wall Street analysts and bankers focused on cannabis investing who also maintain a cannabis stock index, the article listed the 10 largest U.S.-listed companies by market cap -- nine of which were biotech/Pharmaceutical companies.

Medical Marijuana, Inc. came in at No. 6 on the list of powerhouse companies, and investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) came in at No. 5 among the top U.S. cannabis companies. The other top four companies were: 1. GW Pharmaceuticals, 2. Canopy Growth, 3. Insys Therapeutics, 4. Aurora Cannabis.

"With historic, first-ever import approvals for medical cannabis products in Mexico, Columbia and Paraguay, and continued growth of our Brazil business, 2016 was a very exciting year for the Company," said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. "We applaud the news media for covering developments on the financial side, and for savvy investors who are starting to look into the fastest-growing sector in the US."

Meanwhile, AXIM has been added to the North American Marijuana Index, which tracks the leading public cannabis companies operating in the United States and Canada.

Owned by MJIC Inc., the North American Marijuana Index includes companies that have achieved a weighted average minimum market capitalization of $30 million USD, daily trading volume of $400,000 USD and share price of $0.10 USD. Companies with more than $5 million USD of revenue over the prior year are exempt from the above trading requirements and the Index currently has 28 constituents.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact information

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc. Subsidiary, HempMeds(R) Brasil Announces Groundbreaking Distribution Partnership with Paragon HealthCare BR

Jan 05, 2017
OTC Disclosure & News Service

-

Medical Marijuana, Inc. Subsidiary, HempMeds(R) Brasil Announces Groundbreaking Distribution Partnership with Paragon HealthCare BR

Partnership to Provide Expanded Accessibility to RSHO(TM), the First-Ever Product Approved for Import by Brazilian Government

SAN DIEGO, CA--(Marketwired - January 05, 2017) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, has announced a groundbreaking partnership between their subsidiary, HempMeds® Brasil and Paragon HealthCare BR, one of the leading global wholesale distributors of pharmaceutical products.

The partnership between HempMeds® Brasil and Paragon HealthCare BR will provide countless individuals in need of hemp-based medical service more accessibility to HempMeds® Brasil's Real Scientific Hemp Oil™ (RSHO™) line of products. Both pioneers in their respective industries, this newfound partnership provides the opportunity to expose the world to a growing range of products that are showing therapeutic value in international markets.

"This new collaboration with Paragon HealthCare BR is another victory for the hemp industry, and most importantly, for the consumer," said Chief Executive Officer of Medical Marijuana, Inc., Dr. Stuart Titus. "We continue to develop markets, expand partnerships and explore new ways to reach consumers across the globe by providing access to products, like RSHO™, that contain vital nutrients supporting overall health and wellness."

"We look forward to exploring the new horizons that come of this partnership," added Dr. Titus. "We thank Paragon HealthCare BR for joining us in taking a lead in this continually developing marketplace. We cannot grow without innovation and we cannot move forward without a vision. Our distribution partnership with Paragon HealthCare BR is an indication that we will continue to progress and expand our reach both on domestic fronts and abroad."

"We are truly excited to be a part of this opportunity with HempMeds® Brasil and are delighted they selected Paragon HealthCare BR. to become their exclusive distributor for Brasil," said Marcelo Lopes da Silva, VP of International Sales, Paragon Healthcare BR. "We look forward to fully engaging the Brazilian market with the HempMeds® Brasil product line. The company's product line will join our entire suite of products for the Brazilian market to better serve patient needs."

This new partnership with Paragon HealthCare BR, will allow HempMeds® Brasil to expand its outreach in the industry by providing improved access to people of Latin America. Paragon HealthCare BR, a specialty pharmaceutical products distributor, has significant relationships with medical professionals, doctor's groups, hospitals, pharmacists and other health care providers. The venture will focus on making accessibility of products to those in need, assisting individuals to find the medical care needed and then accessing product via special importation permit. In the long run, this will ultimately reduce the time frame from prescription-to-delivery for patients.

Further, there are numerous potential indications for usage of CBD, which will be determined by clinical study and research endeavors. Here, Paragon Health Care BR also provides a wealth of doctors and clinics ready for such research. Recently a Brazil doctor wrote a prescription for microcephaly and HempMeds/Paragon are excited to explore clinical possibility for developmentally challenged children as well as with other neurological indications.

About HempMeds® Brasil

HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact information

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC-MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Copyright © 2017 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc. Featured in L.A. Weekly Profile Story Covering Historic Export Agreements With Mexico, Other Latin American Nations

Dec 29, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc. Featured in L.A. Weekly Profile Story Covering Historic Export Agreements With Mexico, Other Latin American Nations

Article Features Unique Nature of Export Agreement of Cannabis-Related Products From Southern California to Latin America

SAN DIEGO, CA--(Marketwired - December 29, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company, its subsidiary HempMeds® Mexico and its products were featured in an L.A. Weekly article focused on the first-ever import permit granted by Mexico for the cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™).

The Dec. 23, 2016, article titled "Mexico Begins Importing Medical Marijuana As Views on Therapeutic Cannabis Evolve" states, "The California-based company's partnership with Mexico -- an ally of particular interest thanks to cultural and historical ties that date back centuries -- was solidified earlier this year when COFEPRIS, the Mexican health department, approved the country's first permit allowing the import of hemp-based CBD oil across its border." The article goes on to describe how the company worked with attorneys representing families -- who then worked with COFEPRIS to develop a "THC-free" version, called RSHO-X™.

The article continues: "But in Mexico, cannabis-based treatment is viewed with suspicion and remains highly taboo. So when the Maldonado family discovered that another Mexican family had a child with the same kind of affliction, the two families combined their efforts and participated in a series of congressional hearings in Mexico City in January. On February 1, 2016, they were rewarded when COFEPRIS granted permits for the little girls to receive CBD treatments from abroad."

"We are very humbled to have this opportunity," the L.A. Weekly article quoted Medical Marijuana, Inc. CEO Dr. Stuart Titus as saying. "Today, we remain the only legal cannabis-based products allowed into the country and remain the only Botanical CBD company with a COFEPRIS import permit."

The article also discussed Medical Marijuana, Inc. subsidiary HempMeds® Brasil receiving the first-ever import permit from the federal government of Brazil, stating: "Brazil has a similar arrangement with Medical Marijuana, Inc., whose hemp oil was first allowed in the country in 2014 on a case-by-case basis for the treatment of chronic pain, epilepsy and Parkinson's disease."

"We helped educate the government [in Brazil] and, going further, the government saw this product actually helped control these seizure disorders. Since there wasn't a good pharmaceutical medication, the regulatory officials declared it would be "inhumane" to keep these products from the patients," Titus was quoted as saying.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About HempMeds® Mexico

HempMeds® Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company's website at: http://www.hempmeds.mx.

About HempMeds® Brasil

HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc.'s Year in Review: 2016 Vote for Cannabis Reform in 8 States, International Expansion Highlights Historic Year

Dec 28, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc.'s Year in Review: 2016 Vote for Cannabis Reform in 8 States, International Expansion Highlights Historic Year

Company Releases Recap Report of Activities in 2016 and Announces Excitement for Coming Year

SAN DIEGO, CA--(Marketwired - December 28, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced the release of a 2016 business year in review posted to their website HERE. As you can view HERE, Medical Marijuana, Inc. has long been "A Company of First." 2016 continued to show the company's progress with many firsts including; receiving the first-ever import permit from the Mexican federal government, receiving the world's first patented cannabinoid controlled-release chewing gum and becoming the first-ever DEA permit granted to a US-based company to import pharmaceutical grade cannabidiol. Additionally, they participated in first-ever events like the Doctors Symposium in Mexico, ExpoMede Weed in Medellin, Colombia and Genesis in San Diego.

This recap highlights various exciting business activities and developments within Medical Marijuana, Inc.'s diverse investments and portfolio companies throughout the year and shares the enthusiasm for the future of the Company. The Company began the year with the momentum started in 2015 with legislative reform in the sector and a growing need for access to hemp products throughout the U.S. and around the world.

HempMeds

Medical Marijuana, Inc.'s subsidiary and predominate consumer brand, HempMeds® saw a year of massive expansion and continued growth of its line of cannabidiol (CBD) hemp oil products. After receiving the first-ever import permit from Brazil for Real Scientific Hemp Oil™ (RSHO™) in 2014, HempMeds® accomplished the first-ever import permits for its RSHO™ and RSHO-X™ products from the federal governments of Mexico and Paraguay in 2016.

Operating highlights for 2016 included:

HempMeds® welcomed THC-free product RSHO-X™ to its product offering and launched a world-class website redesign featuring unparalleled user connectivity, and launched a first-of-its-kind affiliate program.
HempMeds® increased its wholesale business by more than 50% with continued plans to grow this side of the company in 2017.

With the largest staff in the history of the company, HempMeds® traveled throughout the country showcasing its products at tradeshows such as American Academy of Anti-Aging Medicine Conferences in both Las Vegas and Mexico City, expanding education about CBD and brand awareness to the organization's membership base of more than 26,000 medical and healthcare professionals.

HempMeds® sponsored the nonprofit Hope4Harper foundation's 5K charity run and fundraiser for CDKL5 research and awareness, the Run4Hope, in September in Dallas, Texas.

Medical Marijuana, Inc. CEO, Dr. Stuart Titus, was a featured speaker on medical research at the Cannabis World Congress and Business Expo in New York City in June.

Titus also presented on medical research at the Southern California Cannabis Conference and Expo in San Diego in August.

HempMeds® also continued its CBD education campaign as a sponsor and exhibitor at the Cannabis World Congress and Business Exposition in Los Angeles and Supply Side West in Las Vegas.
Media exposure expanded significantly in 2016. Media coverage included:

Forbes, "The Cannabis Market That Could Grow 700% By 2020"
NewsWeek, "Fiebre por el cannabis"
Forbes Mexico, "Dr. Titus, el estadunidense que le viene a vender marihuana a los mexicanos"
Associated Press, "Paraguay importará aceite de marihuana de Estados Unidos"
Business Insider, "Mexico may be the next frontier for medical marijuana"
Reuters, "AXIM bags pot discount for gum to treat multiple sclerosis"
Bloomberg, "Weeks From Selling Pot, Uruguay Producer Sees Future in Hemp"
Fox Business, "Is Marijuana Chewing Gum The Next Big Thing?"
Fox News Channel: "Harper's legacy: Family donates 5-year-old's brain to science after death from rare condition"
ABC News Nightline's national election coverage: "KGTV San Diego Provides Live Coverage of Prop 64 Celebration Downtown"
NBC News, "NBC 7 Football Night in San Diego"
Fox 5 News San Diego,"San Diego-Based Medical Marijuana Approved to Import Into Mexico"
CW6 News San Diego,"Report on the SoCal Cannabis Conference and Expo"
ABCNews.com, "Live From the Floor of the Cannabis World Congress and Business Expo"
Fox 5 News New York, "Fox 5 NY Interviews Medical Marijuana, Inc. CEO Dr. Stuart Titus at New York Cannabis Expo"
Trade shows and expos featuring products from HempMeds included:

January 9-13: A4M -- Mexico City
February 27-28: Southwest Cannabis Conference and Business Expo -- Dallas / Fort Worth
March 2-4: Betances Pharmacy Business Conference -- Puerto Rico
June 15-17: Cannabis World Congress and Business Expo -- New York
August 6-7: Southern California Cannabis Conference and Expo -- San Diego
September 7-9: Cannabis World Congress and Business Expo -- Los Angeles
September 17: Hope4Harper's Run4Hope -- Dallas
October 4-8: Supplyside West -- Las Vegas
October 20-22: New West Summit -- San Francisco
December 14-16: A4M -- Las Vegas
Continuing the Company's community outreach efforts, the Company donated to its preferred charitable partner in Mexico, the Por Grace Foundation, and efforts to create awareness of CBD hemp oil and education expanded throughout Mexico and Latin America in 2016. In addition, HempMeds® supported Hope4Harper's nonprofit efforts to raise funds for research and awareness of CDKL5.

HempMeds Mexico

With a focus on International expansion, Medical Marijuana, Inc. established its subsidiary HempMeds® Mexico after its flagship THC-free product RSHO-X™ became the first cannabis product to be allowed for import into the country by COFEPRIS. The historic first-ever import permits were awarded to two Mexico girls: Alina Maldonado Montes de Oca and Maria Paula Acevedo Cardos on February 1, 2016.

Since the first import permit was granted, COFEPRIS has allowed for the importation of RSHO-X™ for treatment of multiple medical indications, including chronic pain and diabetic neuropathy -- and HempMeds® Mexico's operation have expanded to accommodate more than 150 patients in Mexico. Dr. Carlos Aguirre, a Mexican physician, conducted and released a study of patients using RSHO-X™ and other CBD products that rendered extremely positive results, including an average seizure reduction of 67% within his patient population with zero negative side effects.

In October, HempMeds® Mexico hosted the country's first-ever Doctors Symposium entitled, "Cannabidiol, usos medicos y terapeuticos, 1er congreso nacional" in Mexico City aimed at educating medical professionals on the benefits of CBD and the proper way to prescribe it. Renowned Mexican physician Dr. Saul Garza Morales spoke at the event on the benefits of CBD. After partnering with nonprofit CBD advocacy group Por Grace, Mexican President Enrique Pena Nieto credited Raul Elizalde, the organization's founder, and his daughter Grace and families like them for "changing his mind and the course of the country's cannabis policies based on science and human rights." The Senate voted 98-7 a few weeks later on a bill to allow space to medical cannabis in their country. HempMeds® Mexico's RSHO-X™ remains the only cannabinoid product COFEPRIS has approved for importation into the country. In addition to serving Mexico, HempMeds® Mexico expanded its distribution into other Latin American countries such as Argentina, Chile, and Colombia where it attended the first-ever ExpoMede Weed in Medellin, Colombia. Additionally, the company began importing its product RSHO-X™ into Paraguay which was covered by media giant Associated Press and many national TV outlets.

Since the historic, first-ever approval for a US-based cannabis product to be imported into Mexico, that development has been covered by literally hundreds of media outlets globally. Find a full list of them HERE.

Kannaway

Kannaway, the Company's premier lifestyle marketing brand and subsidiary company, spent the year refreshing and relaunching its world-renowned brand that all began with a March 29 announcement of its new executive team with Bradley J. Tayles being named President and newly appointed CEO, Blake Schroeder. The two new additions brought years of experience and a fresh outlook on the industry. Throughout the year, Kannaway introduced multiple new products, including Kannaway Premium Hemp Oil and Kannaway Pure CBD, which have taken the CBD market by storm.

With the new management at the helm, the company added a stock incentive program for its brand ambassadors' as well as launched new trainings aimed at helping affiliates find success with the company. With the goal of reaching the masses, Kannaway became bilingual in its marketing offerings and hosted three regional events across the country, as well as its first-ever national event in San Diego in November called "Genesis." The event attracted hundreds of participants and featured announcements including: updates to the compensation plan, new packaging and brand materials, release of a new corporate video, and a complete website redesign. Finally, the company experienced a more than 400% growth in monthly revenue at year-end compared to April of this year and forecasts are looking even more positive for 2017.

HempMeds Brasil

Continuing its international expansion efforts, Medical Marijuana, Inc. subsidiary HempMeds Brasil™ continued to offer its world-renowned CBD product RSHO™ as the first-ever cannabis product approved by ANVISA for importation into the country. The company, under new management this year, was able to offer two new products to Brazilian citizens, RSHO-X™ and a liquid version of its famed RSHO™ product line, all while decreasing importation time to only three days from order to arrival.

The company also continued to be instrumental in creating access to medical cannabis in Brazil, where they work with thousands of families in need of help gaining legal access to RSHO™ to help with many conditions including; Epilepsy, Parkinson's, Chronic Pain and Cancer.

Since the historic 2014 court case, the company has repeatedly attracted national media attention after the government approved CBD for import for multiple medical indications and also started subsidizing the payments under the government health care system. You can find a full report of the many media success stories throughout the year HERE.

Meanwhile in 2016, the court cases of consumers in Brazil fighting for access to RSHO™, and an open letter that Medical Marijuana, Inc. CEO, Dr. Stuart Titus, wrote to Brazilians in August, continued to make headlines in 2016.

AXIM Biotechnologies

Major Investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) in which The Company owns 22,143,650 common shares or about 40%, had the most exciting year in the company's history beginning with the announcement of dermatological clinical research on cannabigerol (CBG) for treatment of psoriasis and eczema that was covered by Forbes.

Soon after that groundbreaking announcement, AXIM® announced that they had received the necessary funding to continue its clinical research program on its proprietary method of chewing gum as a delivery mechanism for CBD and other cannabinoids, which was recently covered by Fox Business. Included in their program pipeline is breakthrough invention MedChew Rx™, the world's first patented cannabinoid controlled-release chewing gum, which is on pace to be fully registered by the EMA and FDA by the end of 2018. Featured by Reuters global news agency, MedChew Rx™ will change the way that medicine is delivered to patients worldwide. Directly compared to a sublingually delivered cannabis-based product currently on the market for multiple sclerosis (MS) in the Reuters article, the potential economic impact for MedChew Rx™ is estimated at $4.8 billion USD -- for spasticity and pain associated with MS.

Shortly thereafter the company announced that it had entered the gum into a PK/PD study and received medical ethical committee approval from the University of Wageningen to begin human clinical trials using its product CanChew® Plus for treatment of Irritable Bowel Syndrome (IBS).

As a part of their intellectual property portfolio, the company announced that it has received an extension of its patent from the World Intellectual Property Organization (WIPO) and USPTO to include the delivery mechanism of all cannabinoids through chewing gum. In addition to that extension, the company was assigned the patent on its proprietary method of THC extraction that rendered the purest form of THC known in the field. Additionally, the company significantly expanded its IP and TM portfolio and formulated numerous potentially blockbuster preparations, which will be investigated in the coming months and years. Finally, AXIM® added multiple world-class specialists to its advisory board and delighted investors and shareholders by releasing its product pipeline through 2020. AXIM was voted one of 5 top-performing biotech stocks for 2016 by Fox Business News.

Kannalife Sciences

Portfolio company Kannalife Sciences is a late-stage biotechnology company involved with the pharmaceutical development of new therapeutic compounds based on cannabinoids. KannaLife has garnered a licensing agreement with the United States National Institutes of Health (NIH) for two indications: (1) Hepatic Encephalopathy (HE) and secondly for traumatic head injury, known as (2) Chronic Traumatic Encephalopathy (CTE). Hepatic encephalopathy is the occurrence of confusion, altered level of consciousness, and/or coma as a result of liver failure. CTE is a progressive degenerative disease found in people who have had a severe blow or repeated blows to the head.

Conducting their research under this US government license, Kannalife continued to make headlines with the announcement of a patent on a new CBD-like compound, named KLS-13019. The interest of this was to advance a therapeutic candidate for serious neurological disorders. While CBD is effective for these disorders there are limitations that where modified and designed for greater "drug likeness." KLS-13019 was found to be 50-fold more potent and greater than 400-fold safer than CBD and exhibited a profile consistent with improved oral bioavailability. This discovery of the body of science behind KLS-13019 was published by the American Chemical Society.

Kannalife also made headlines in March after receiving the first-ever DEA permit granted to a US-based company to import pharmaceutical grade cannabidiol to continue their feasibility studies to help treat HE and CTE. The company's NIH license to research a treatment for CTE was also featured in a major article by Sports Illustrated.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc. Releases In-Depth Video Series Featuring New Executive Team and Lives Strengthened by Company's Products

Dec 22, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc. Releases In-Depth Video Series Featuring New Executive Team and Lives Strengthened by Company's Products

Company Provides Real-Life Testimony Displaying Its Origins, Unprecedented Firsts and Major Accomplishments in 2016

SAN DIEGO, CA--(Marketwired - December 22, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, has announced the release of an in-depth video series showcasing the Company's history and unprecedented accomplishments as a "Company of Firsts." From establishing the nation's first cannabidiol (CBD) oil pipeline from Europe to the U.S. to creating a standard for lab testing of cannabis products, the video series highlights the many ground-breaking achievements of Medical Marijuana, Inc. and what the future holds.

As part of an outreach campaign, the company has decided to highlight various individuals that have been affected by the company's now ever-expanding presence around the globe. The video marks a milestone in the company's consistent rise as one of the foremost leaders in the medical cannabis and hemp industry.

The series can be accessed for viewing on www.medicalmarijuanainc.com. In addition to personal stories of success, the video brings viewers on a journey that follows the rise of the company, from its beginnings as a startup to its standing as one of the leading innovators in the cannabis and hemp industry.

"In the case of our new video series, seeing really is believing," said Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. "We are honored to bring our story of hope to the world. It is one thing to hear about the transformative effects of our products, or to read about it in research studies. But starting today, you can now see the real-life impact our products offer to countless lives around the world."

Dr. Titus added, "There are many who suffer in silence and whose calls for help go unanswered. However, because of the strides made by our company, I am pleased to say that we are beginning to answer those calls. This video is our chance to tell the world that we hear your pain. I am confident that with our continued strides in the cannabis and hemp industry, we will make the world a better place."

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact information
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc. Subsidiary HempMeds Brasil(TM) Begins Importation of Real Scientific Hemp Oil-X(TM) Product Line Into Brazil

Dec 21, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc. Subsidiary HempMeds Brasil(TM) Begins Importation of Real Scientific Hemp Oil-X(TM) Product Line Into Brazil

Consumers Looking for Zero THC Version of Real Scientific Hemp Oil (RSHO(TM)) Products Now Have Solution From First-Ever Approved Company

SAN DIEGO, CA--(Marketwired - December 21, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Real Scientific Hemp Oil-X™ (RSHO-X™) product line is now being imported into Brazil through the company's subsidiary, HempMeds Brasil™.

The RSHO-X™ product line was developed as the first tetrahydrocannabinol (THC)-free hemp oil product on the market. Originally developed to fit Mexico's strict import regulations, RSHO-X™ was the first cannabis product ever legally imported into Mexico.

Recently, Dr Carlos Aguirre performed an informational study in Mexico where he used RSHO-X™ on various patients and children suffering from Epilepsy. Dr. Aguirre saw an average seizure reduction of 67% within his patient population, all with no adverse side effects. The results from this study will soon be published in Neurology Research International, an open access, peer-reviewed open access journal that publishes original research articles, review articles and clinical studies in all areas of neurology.

This RSHO-X product would be the first cannabis based product to actually qualify for World Anti-Doping standards, so that professional sport, Olympic athletes can take without fear of failing a drug screening.

"Our company was honored to create and distribute the first cannabis product to be approved for import and use in Brazil through medical prescription -- we are excited to offer this important new hemp oil product line to the customers there," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "In line with our mission to bring cannabinoid access to all, RSHO-X™ opens up a growing market of customers looking to avoid THC but still experience the similar benefits awarded those who enjoy our traditional CBD hemp oil products."

"HempMeds Brasil™ has been instrumental in creating access to medical cannabis in Brazil and we will continue to educate the medical community and regulatory agencies to make the process for obtaining cannabis products like RSHO-X™ easier," added Dr. Titus.

RSHO-X™ is the preferred hemp oil supplement for those looking to completely avoid even trace amounts of THC and fits the requirements of anyone liable to drug tests. These RSHO-X™ users could range from:

First responders such as firefighters and police officers that deal with physical exertion and stress and must fit their employer's restrictions on cannabis use.
Veterans and active military personal who have restrictions from Veterans Affairs policies, despite several studies conducted on the potential benefits of cannabis for veterans suffering with PTSD.
Competing athletes who face restrictive cannabis testing policies for the sports' governing bodies. RSHO-X™ in the first cannabidiol (CBD) hemp oil product able to pass the restriction on cannabis set forth by the World Anti-Doping Agency, enabling athletes to enjoy the benefits of CBD without fear of negative consequences.
Parents looking to supplement their child with CBD hemp oil but wish to avoid exposing them to even trace amounts of THC, allowing them to benefit the balancing effects cannabinoids have on the human body.
About HempMeds Brasil™

HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

The following files are available for download:

logo 1
RSHO-X-Table
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc. Subsidiary HempMeds Brasil(TM) Welcomes Caroline Heinz to Executive Team

Dec 20, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc. Subsidiary HempMeds Brasil(TM) Welcomes Caroline Heinz to Executive Team

Ms. Heinz Joins HempMeds Brasil(TM) Team as New Director of Operations for Brazil-Based Company

SAN DIEGO, CA--(Marketwired - December 20, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that Caroline Heinz has been appointed as the new Director of Operations for their subsidiary, HempMeds Brasil™.

Heinz has played a vital role as part of the HempMeds Brasil™ team since its launch in 2014, working on brand development and marketing. Previous to her involvement with HempMeds Brasil™, Heinz worked in numerous high-level positions in various Brazilian and U.S. organizations such as world renowned media outlet TV Globo.

Ms. Heinz earned her Masters of Business Administration degree from San Diego University for Integrative Studies, and holds a Bachelor's degree in Social Communications from UNIVERCIDADE, in Rio de Janeiro, Brazil, majoring in Journalism.

"Ms. Heinz has been an integral part of the HempMeds Brasil™ team for many years now and we are very glad to announce her promotion Director of Operations for the company, a division of Medical Marijuana, Inc. (OTC PINK: MJNA)," said Chief Executive Officer, Dr. Stuart Titus. "When Real Scientific Hemp Oil™ (RSHO™) became the first medical cannabis product to be approved for import and use in Brazil, we knew that this was a huge opportunity and very important market for our company to be part of. We believe that Ms. Heinz has the talent to continue the upward momentum that HempMeds has in this emerging cannabinoid market within Brazil."

With the approval of RSHO™, Brazil also became the first Latin American country to approve prescriptions for any medical cannabis product, with Mexico and Paraguay following suit - issuing the first-ever approvals for Medical Marijuana, Inc. products in both countries.

"HempMeds Brasil™ has been instrumental in creating access to medical cannabis in Brazil, were we work with thousands of families in need of help gaining legal access to RSHO™," Heinz said. "I am beyond excited about taking on this new responsibility for a company that I fully believe in, which is working hard to educate the medical community and regulatory agencies to make the process for obtaining cannabis products like RSHO™ easier."

About HempMeds Brasil™

HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact information
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Investor Relations Contact:
EquiNet, LLC
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: info@equinet.us
www.equinet.us


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc., una subsidiaria de HempMeds(R), anuncia la creación de operaciones comerciales en Chile e inicia la importación a Argentina

Dec 15, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc., una subsidiaria de HempMeds(R), anuncia la creación de operaciones comerciales en Chile e inicia la importación a Argentina

La empresa continúa sus iniciativas de expansión internacional con la formación de una empresa en Chile e inicia la importación de Real Scientific Hemp Oil(TM) al mercado argentino

SAN DIEGO, CA--(Marketwired - 15 de diciembre de 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), la primera empresa de cannabis que cotiza en bolsa en los Estados Unidos, anunció hoy que su subsidiaria HempMeds® ha constituido una nueva empresa en Chile. Además, como parte de su iniciativa de expansión al mercado latinoamericano, la empresa ya ha comenzado a importar a Argentina su principal producto Real Scientific Hemp Oil™ (RSHO™).

Esta nueva expansión latinoamericana se produce después de que la empresa recibiera la primera aprobación federal de la COFEPRIS para importar un producto de cannabis a México, junto con las otras dos primeras aprobaciones históricas para importar RSHO™ a Brasil y Paraguay.

"Estamos orgullosos de estar construyendo una empresa en Chile y expandiendo nuestra distribución de HempMeds®RSHO™ a más países de Latinoamérica". Otros países de la región, como es el caso de Brasil, Paraguay y México, han legalizado los productos CBD para el tratamiento de varias indicaciones médicas, de manera que desarrollar una presencia empresarial en Chile y una red de distribución en Argentina parecía la mejor dirección lógica", dijo el CEO de Medical Marijuana, Inc., el Dr. Stuart Titus. "Estamos entusiasmados con el nuevo emprendimiento y esperamos ayudar a desarrollar nuevas oportunidades económicas para la gente de Chile y Argentina".

"La nueva legislación, como la reciente decisión de Argentina de permitir la importación del aceite de cannabis representa un paso gigantesco de nuestro objetivo continuo de educar al mundo sobre las potenciales ventajas médicas que pueden proporcionar los cannabinoides". Creemos que Chile será uno de nuestros mercados más grandes en América Latina debido a estas nuevas regulaciones y al plan del gobierno para sufragar los productos para los ciudadanos en el futuro", agregó el Dr. Titus.

En Chile, ha habido muchas novedades desde la aprobación de una medida que legaliza el cultivo y la venta de marihuana con fines medicinales en 2015 que proporcionó marihuana medicinal gratuita a casi 4.000 pacientes. A principios de este año, el país inauguró la mayor granja de marihuana medicinal en América Latina. Además, la presidenta de Chile, Michelle Bachelet firmó un decreto para eliminar la marihuana de una lista de drogas peligrosas. El decreto también permite que la marihuana medicinal se venda en las farmacias, ofreciéndoles un mayor acceso a los pacientes.

Acerca de HempMeds ®

HempMeds® que creó el primer "canal de suministro de CBD" en los Estados Unidos, es una compañía de la cartera de empresas de Medical Marijuana, Inc. (OTC PINK: MJNA) y el principal distribuidor exclusivo y compañía de marketing por contrato de la Compañía. HempMeds ofrece legalmente al mercado estadounidense una amplia gama de productos de cannabis y CBD en los 50 estados.

Acerca de Medical Marijuana, Inc.

Nuestra misión es convertirnos en los principales innovadores en la industria de cannabis y cáñamo, aprovechando nuestro equipo de profesionales para buscar, evaluar y adquirir compañías y productos de valor agregado, a la vez que les permitimos mantener su integridad y su espíritu emprendedor. Nos esforzamos por crear conciencia dentro de nuestra industria, desarrollar negocios ecológicos y económicamente sostenibles y, a su vez, aumentar el valor para los accionistas. Para obtener más información acerca de la cartera y las compañías de inversión de Medical Marijuana, Inc., ingrese en www.medicalmarijuanainc.com.

Para ver la declaración en video de Medical Marijuana, Inc., haga clic aquí. Se recomienda a los accionistas que visiten también Medical Marijuana, Inc. Shop en cuanto a productos con descuento.

DESCARGO DE RESPONSABILIDAD SOBRE DECLARACIONES PROSPECTIVAS

Este comunicado de prensa puede contener ciertas declaraciones e información de carácter prospectivo, tal como se define en la sección 27A de la Ley de Valores de 1933 y la sección 21E de la Ley de Bolsas de Valores de 1934 y está sujeto a las disposiciones de puerto seguro establecidas por dichas secciones. Este material contiene declaraciones acerca de futuros eventos o resultados financieros esperados que son de naturaleza prospectiva y están sujetos a riesgos e incertidumbres. Tales declaraciones prospectivas por definición conllevan riesgos, incertidumbres y otros factores que pueden causar que los resultados reales, el rendimiento o los logros de Medical Marijuana, Inc. sean sustancialmente diferentes a las declaraciones emitidas en este comunicado.

DECLARACIÓN DE LA ADMINISTRACIÓN DE DROGAS Y ALIMENTOS (FDA)

Estas declaraciones no han sido evaluadas por la FDA y no tienen el propósito de diagnosticar, tratar ni curar ningún tipo de enfermedad.

DIVULGACIÓN LEGAL

Medical Marijuana Inc. no vende ni distribuye ningún producto que infrinja la Ley de Sustancias Controladas de los Estados Unidos (US.CSA). Estas compañías producen, venden y distribuyen productos con aceite de cáñamo y participan en la distribución legal a nivel federal de productos medicinales que contienen marihuana dentro de determinados mercados internacionales. El cannabidiol es un ingrediente natural del aceite de cáñamo.

Información de contacto

Contacto de Relaciones Públicas:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Contacto de Negocios Corporativos:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
Símbolo OTC: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Contacto de Relaciones con Inversores:
EquiNet, LLC
Línea gratuita: (877) 964.6463
Oficina/Directo: (858) 264-6500
Email: info@equinet.us
www.equinet.us


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.



Medical Marijuana, Inc., subsidiária da HempMeds(R) anuncia criação de empresa no Chile, início de importação para a Argentina

Dec 15, 2016
OTC Disclosure & News Service

-

Medical Marijuana, Inc., subsidiária da HempMeds(R) anuncia criação de empresa no Chile, início de importação para a Argentina

Empresa dá continuidade a suas iniciativas de expansão internacional com criação de empresa no Chile e início de importação do Real Scientific Hemp Oil(TM) para a Argentina

SAN DIEGO, CA--(Marketwired - 15 de dezembro de 2016) - A Medical Marijuana, Inc. (OTC PINK: MJNA), primeira empresa de cannabis comercializada publicamente nos Estados Unidos, anunciou hoje que a sua subsidiária HempMeds® criou uma nova empresa no Chile. Além disso, como parte da sua iniciativa de expansão no mercado da América Latina, a empresa deu início à importação do seu principal produto, Real Scientific Hemp Oil™ (RSHO™) para a Argentina.

Esta nova expansão para a América Latina dá seguimento à primeira aprovação federal do COFEPRIS para a importação de produto de cannabis no México, juntamente com duas outras aprovações históricas para a importação do RSHO™ para o Brasil e Paraguai.

"Estamos orgulhosos com a criação da nossa empresa no Chile e com a expansão da distribuição do HempMeds®RSHO™ para mais países na América Latina. Outros países da região, tais como Brasil, Paraguai e México, legalizaram os produtos CBD para tratamento de vários problemas médicos, por isso uma empresa no Chile e uma rede de distribuição para a Argentina foi o melhor direcionamento lógico para a empresa", disse o CEO da Medical Marijuana, Inc., Dr. Stuart Titus. "Estamos muito contentes com o novo empreendimento e esperamos poder ajudar na criação de novas oportunidades econômicas para as pessoas do Chile e da Argentina".

"Novas legislações, tal como a decisão da Argentina de autorizar a importação do óleo de cannabis, são um passo gigantesco em direção da nossa meta contínua de educar o mundo sobre as vantagens médicas em potencial que os canabióides podem proporcionar. O Chile será um dos nossos maiores mercados na América Latina devido a esses novos regulamentos e o plano do governo de pagar pelos produtos para a população no futuro", acrescentou o Dr. Titus.

O Chile teve muito avanço desde a aprovação de uma lei que legaliza o cultivo e a venda de marijuana para fins medicinais em 2015, que proporciona a quase 4.000 pacientes marijuana medicinal gratuitamente. No início do ano, o país inaugurou sua maior fazenda de marijuana medicinal da América Latina. A presidente do Chile, Michelle Bachelet assinou uma lei para a remoção da marijuana da lista de drogas perigosas. A medida também permite que a marijuana médica seja vendida nas farmácias, dando aos pacientes maior acesso.

HempMeds ®

A HempMeds®, que criou o primeiríssimo "pipeline de CBD" nos Estados Unidos, é uma empresa de portfólio corporativo da Medical Marijuana, Inc. (OTC PINK: MJNA), e é a distribuidora exclusiva da Empresa e empresa de marketing contratada. A HempMeds oferece uma ampla variedade de produtos de cannabis e de CBD legalmente nos 50 estados dos Estados Unidos.

Medical Marijuana Inc.

Temos por missão ser o principal inovador do mercado de cannabis e hemp, utilizando nossos profissionais para obter, avaliar e comprar empresas e produtos de valor agregado, mantendo sua integridade e espírito empresarial. Buscamos disseminar o conhecimento na nossa indústria, desenvolver empresas ambientalmente positivas e economicamente sustentáveis, e aumentar o valor dos acionistas. Para mais detalhes sobre as empresas do portfólio e de investimentos da Medical Marijuana, Inc., visite www.medicalmarijuanainc.com.

Para ver o vídeo com a declaração da Medical Marijuana, Inc., clique aqui. Os acionistas também devem visitar o site Medical Marijuana, Inc. Shop para ver a lista de produtos oferecidos com desconto.

DECLARAÇÕES DE PREVISÃO

Este press release pode conter certas declarações e informações de previsão, de acordo com o disposto na Seção 27A do Securities Act of 1933 e Seção 21E do Securities Exchange Act of 1934, sujeitas ao regulamento de Safe Harbor estabelecido por tais seções. Este material contém declarações sobre eventos e/ou resultados futuros esperados que são consideradas declarações de previsão sujeitas a riscos e incertezas. Tais declarações de previsão, por definição, envolvem riscos, incertezas e outros fatores, que podem fazer com que os resultados, desempenho ou conquistas reais da Medical Marijuana, Inc. sejam substancialmente diferentes dos resultados previstos.

DECLARAÇÃO DA FOOD AND DRUG ADMINISTRATION (FDA) DOS EUA

Estas declarações não foram analisadas pela FDA e não têm por objetivo diagnosticar, tratar ou curar nenhuma doença.

DECLARAÇÃO LEGAL

A Medical Marijuana Inc. não vende nem distribui nenhum produto que violem a lei United States Controlled Substances Act (US.CSA). Estas empresas cultivam, vendem e distribuem produtos de hemp e estão envolvidas na distribuir legal de produtos medicinais de marijuana para certos mercados internacionais. Cannabidiol é um ingrediente natural do hemp oil.

Informação de Contato

Contato de Relações Públicas:
Andrew Hard
CEO
CMW Media
P. 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Contato Comercial:
Nicholas R. Massalas
Diretor de Desenvolvimento Comercial
Medical Marijuana, Inc.
Símbolo OTC: MJNA
Ligação Gratuita: 888-OTC- MJNA (888-682- 6562)
www.medicalmarijuanainc.com
www.facebook.com/mjnainc

Contato de Relação com o Investidor:
EquiNet, LLC
Ligação Gratuita: (877) 964.6463
Escritório/Direto: (858) 264-6500
Email: info@equinet.us
www.equinet.us


Copyright © 2016 Marketwired. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.